C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease
出版年份 2023 全文链接
标题
C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease
作者
关键词
-
出版物
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 82, Issue 5, Pages 414-426
出版商
Elsevier BV
发表日期
2023-07-25
DOI
10.1016/j.jacc.2023.05.035
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cohort profile: the Utrecht Cardiovascular Cohort–Second Manifestations of Arterial Disease (UCC-SMART) Study–an ongoing prospective cohort study of patients at high cardiovascular risk in the Netherlands
- (2023) Maria C Castelijns et al. BMJ Open
- Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
- (2021) Paul M Ridker et al. CIRCULATION RESEARCH
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race
- (2021) Lesley A. Inker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetically Determined Inflammatory Biomarkers and the Risk of Heart Failure: A Mendelian Randomization Study
- (2021) Xintao Li et al. Frontiers in Cardiovascular Medicine
- Mortality after hospital admission for heart failure: improvement over time, equally strong in women as in men
- (2020) J. Buddeke et al. BMC PUBLIC HEALTH
- Inflammation in Heart Failure
- (2020) Sean P. Murphy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Epidemiology of heart failure
- (2020) Amy Groenewegen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Colchicine in Patients with Chronic Coronary Disease
- (2020) Stefan M. Nidorf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-Inflammatory Therapy with Canakinumab for the Prevention of Hospitalization for Heart Failure
- (2019) Brendan M. Everett et al. CIRCULATION
- The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study
- (2019) Cilie C van’t Klooster et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
- (2019) Jean-Claude Tardif et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction
- (2018) Rudolf A. de Boer et al. JAMA Cardiology
- Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
- (2018) Fabrice Bonnet et al. DIABETES & METABOLISM
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials
- (2015) David Preiss et al. EUROPEAN HEART JOURNAL
- White Blood Cell Count, C-Reactive Protein, and Incident Heart Failure in the Atherosclerosis Risk in Communities (ARIC) Study
- (2011) Wobo Bekwelem et al. ANNALS OF EPIDEMIOLOGY
- Inflammatory Markers and Incident Heart Failure Risk in Older Adults
- (2010) Andreas Kalogeropoulos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Metabolic Syndrome, Inflammation, and Incident Heart Failure in the Elderly
- (2008) Takeki Suzuki et al. Circulation-Heart Failure
- Tracking of High-Sensitivity C-Reactive Protein after an Initially Elevated Concentration: The JUPITER Study
- (2008) R. J. Glynn et al. CLINICAL CHEMISTRY
- The Evolving Role of C-Reactive Protein in Atherothrombosis
- (2008) S. Devaraj et al. CLINICAL CHEMISTRY
- Novel Metabolic Risk Factors for Incident Heart Failure and Their Relationship With Obesity
- (2008) Hossein Bahrami et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started